The company intends to use the proceeds from the Directed Share Issue primarily to finance a new indication for the drug candidate MIV-711, which has the potential to create significant shareholder value: Legg-Calvé-Perthes disease (Perthes), a rare condition in which the femoral head degenerates in children and for which there is currently no approved drug treatment.

“Perthes disease is a rare but serious pediatric condition for which there are currently no approved drug treatments. The strong support for the directed share issue from both existing and new investors enables us to initiate the clinical development of MIV-711 for Perthes disease, which broadens MIV-711’s commercial potential and thereby increases value for our shareholders,” says Jens Lindberg, CEO of Medivir.

Hallberg Management AB’s participation in the Directed Share Issue is subject to approval by the shareholders’ meeting in accordance with Chapter 16 of the Swedish Companies Act, and the board of directors has decided to convene an extraordinary shareholders’ meeting on July 20, 2026.